The Firm is representing Capsugel in its announced acquisition of Xcelience and Powdersize. Completion of the transaction is conditioned upon regulatory approval and other customary closing conditions. The terms of the transaction were not disclosed.
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the healthcare industry. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries.
Xcelience offers a suite of services enabling clients to partner with a single CDMO for all of their global clinical outsourcing needs. Services include preformulation, micronization, analytical services, formulation development, cGMP manufacturing, small-scale commercial manufacturing and global clinical supplies packaging and logistics.
Powdersize is a customer service-driven contract manufacturer, providing expertise in particle-size reduction and particle-size control technologies intended for powders used within the pharmaceutical, medical and food marketplaces. Powdersize is one of the leading contract manufacturers offering milling and micronization services in the United States.
The Simpson Thacher team includes Andrew Smith, Matthew Rogers and Tracy Ke (M&A); Clare Gaskell and Anais Fritz (Corporate - UK); David Rubinsky, Aimee Adler and Joo Hyun Lee (Executive Compensation and Employee Benefits); Nancy Mehlman and Jordan Tamchin (Tax); Krista McManus and Leanne Welds (Real Estate); Lori Lesser and Monica Chan (Intellectual Property); Adeeb Fadil and Noreen Lavan (Environmental); and Michael Naughton and Ken Ehrhard (Antitrust).